Biodexa Pharmaceuticals PLC: Q1 2025 Financial Report Overview

Here are the key points extracted from the financial report (Form 6-K) of Biodexa Pharmaceuticals PLC:

1. Filing Information:

• Document Type: Form 6-K
• Filing Date: February 13, 2025
• Commission File Number: 001-37652

2. Company Information:

• Name: Biodexa Pharmaceuticals PLC
• Address: 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
• Company Type: Foreign Private Issuer

3. Annual Reports:

• The company indicates it files annual reports under Form 20-F.

4. Attached Exhibit:

• The report includes Exhibit 99.1, which is a press release dated February 13, 2025. However, the information in this exhibit is being furnished and is not considered "filed" under the Securities Exchange Act of 1934.

5. Regulatory Compliance:

• The submission complies with Regulation S-T Rule 101, which pertains to the submission of documents by foreign private issuers.

6. Signature:

• The report is signed by Stephen Stamp, who holds the positions of Chief Executive Officer and Chief Financial Officer.

These points provide a clear overview of the filing, the company, and the compliance with SEC regulations. The presence of a press release indicates ongoing communication with stakeholders, which may include financial updates or corporate developments relevant to the company.